Kymera Historical Income Statement
| KYMR Stock | USD 44.98 1.47 3.38% |
Historical analysis of Kymera Therapeutics income statement accounts such as Interest Expense of 132.7 K can show how well Kymera Therapeutics performed in making a profits. Evaluating Kymera Therapeutics income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Kymera Therapeutics's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining Kymera Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Kymera Therapeutics is a good buy for the upcoming year.
Kymera |
About Kymera Income Statement Analysis
Kymera Therapeutics Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Kymera Therapeutics shareholders. The income statement also shows Kymera investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Kymera Therapeutics Income Statement Chart
Add Fundamental
Depreciation And Amortization
The systematic reduction in the recorded value of an intangible asset. This includes the allocation of the cost of tangible assets to periods in which the assets are used, representing the expense related to the wear and tear, deterioration, or obsolescence of physical assets and intangible assets over their useful lives.Total Revenue
Total revenue comprises all receipts Kymera Therapeutics generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Kymera Therapeutics. It is also known as Kymera Therapeutics overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Total Operating Expenses
The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.Most accounts from Kymera Therapeutics' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Kymera Therapeutics current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Kymera Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. To learn how to invest in Kymera Stock, please use our How to Invest in Kymera Therapeutics guide.At this time, Kymera Therapeutics' Net Interest Income is relatively stable compared to the past year. As of 11/25/2024, Interest Income is likely to grow to about 19.7 M, while Interest Expense is likely to drop slightly above 132.7 K.
| 2021 | 2022 | 2023 | 2024 (projected) | Interest Expense | 175K | 176K | 196K | 132.7K | Depreciation And Amortization | 2.4M | 3.0M | 3.6M | 2.3M |
Kymera Therapeutics income statement Correlations
Click cells to compare fundamentals
Kymera Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Kymera Therapeutics income statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Net Interest Income | 959K | 711K | 313K | 6.4M | 18.6M | 19.5M | |
| Interest Income | 1.0M | 826K | 488K | 6.6M | 18.8M | 19.7M | |
| Depreciation And Amortization | 1.8M | 1.8M | 2.4M | 3.0M | 3.6M | 2.3M | |
| Interest Expense | 46K | 115K | 175K | 176K | 196K | 132.7K | |
| Selling General Administrative | 8.0M | 18.2M | 36.3M | 43.8M | 55.0M | 30.3M | |
| Total Revenue | 2.9M | 34.0M | 72.8M | 46.8M | 78.6M | 43.1M | |
| Other Operating Expenses | 45.1M | 80.3M | 173.4M | 208.1M | 244.1M | 141.6M | |
| Operating Income | (42.2M) | (46.3M) | (100.5M) | (161.3M) | (165.5M) | (157.3M) | |
| Net Income From Continuing Ops | (41.2M) | (45.6M) | (100.2M) | (154.8M) | (147.0M) | (139.6M) | |
| Ebit | (42.2M) | (45.5M) | (100.0M) | (154.6M) | (146.8M) | (139.4M) | |
| Research Development | 37.2M | 62.1M | 137.0M | 164.2M | 189.1M | 111.3M | |
| Ebitda | (40.4M) | (43.7M) | (97.6M) | (151.7M) | (143.2M) | (136.0M) | |
| Total Operating Expenses | 45.1M | 80.3M | 173.4M | 208.1M | 244.1M | 141.6M | |
| Reconciled Depreciation | 825K | 1.8M | 2.4M | 3.0M | 3.6M | 2.2M | |
| Income Before Tax | (41.2M) | (45.6M) | (100.2M) | (154.8M) | (147.0M) | (139.6M) | |
| Total Other Income Expense Net | 959K | 711K | 313K | 6.4M | 18.6M | 19.5M | |
| Net Income Applicable To Common Shares | (41.2M) | (54.6M) | (100.2M) | (154.8M) | (139.3M) | (132.4M) | |
| Net Income | (41.3M) | (43.9M) | (98.0M) | (151.8M) | (147.0M) | (139.6M) |
Pair Trading with Kymera Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Kymera Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Kymera Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against Kymera Stock
The ability to find closely correlated positions to Kymera Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Kymera Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Kymera Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Kymera Therapeutics to buy it.
The correlation of Kymera Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Kymera Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Kymera Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Kymera Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Kymera Stock Analysis
When running Kymera Therapeutics' price analysis, check to measure Kymera Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kymera Therapeutics is operating at the current time. Most of Kymera Therapeutics' value examination focuses on studying past and present price action to predict the probability of Kymera Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kymera Therapeutics' price. Additionally, you may evaluate how the addition of Kymera Therapeutics to your portfolios can decrease your overall portfolio volatility.